Messenger rna expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 1, 2010, Pages 1-10

  An, Jiaze ^a   Wei, Qingyi ^a   Liu, Zhensheng ^a   Lu, Karen H ^a   Cheng, Xi ^a   Mills, Gordon B ^a   Wang, Li E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Case control study; DNA repair; Epigenetics; Molecular epidemiology; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA METHYLTRANSFERASE 3B; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; ETHNICITY; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR EPIDEMIOLOGY; OVARY CANCER; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FOLDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 77954641662     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hanna L and Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2006; 20: 339-362.
2. Sankaranarayanan R and Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006; 20: 207-225.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
4. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196.
5. Salozhin SV, Prokhorchuk EB and Georgiev GP. Methylation of DNA--one of the major epigenetic markers. Biochemistry (Mosc) 2005; 70: 525-532.
6. Widschwendter M, Berger J, Muller HM, Zeimet AG and Marth C. Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia 2001; 6: 193-201.
7. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427-5440.
8. Esteller M, Corn PG, Baylin SB and Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229.
9. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK and Plass C. Aberrant CpG-island methylation has nonrandom and tumour-type-specific patterns. Nat Genet 2000; 24: 132-138.
10. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB and Herman JG. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-569.
11. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM and Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumorsuppressor gene. Am J Hum Genet 1991; 48: 880-888.
12. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
13. Mulero-Navarro S and Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008; 68: 1-11.
14. Vaissiere T, Sawan C and Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008; 659: 40-48.
15. Kanai Y and Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007; 28: 2434-2442.
16. Butcher LM and Beck S. Future impact of integrated high-throughput methylome analyses on human health and disease. J Genet Genomics 2008; 35: 391-401.
17. Barton CA, Hacker NF, Clark SJ and O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008; 109: 129-139.
18. Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C and Riva C. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 2006; 12: 3329-3336.
19. Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, Yasugi T and Ushijima T. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Lett 2006; 241: 213-220.
20. Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML and Wei Q. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res 2005; 11: 4968-4976.
21. Liu Z, Wang LE, Strom SS, Spitz MR, Babaian RJ, DiGiovanni J and Wei Q. Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis. Mol Carcinog 2003; 36: 123-129.
22. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV and Laird PW. Methy Light: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28: E32.
23. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S and Karlan BY. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000; 60: 5329-5333.
24. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH and Kim JS. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003; 163: 1551-1556.
25. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG and Meltzer SJ. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59: 1090-1095.
26. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
27. ABI. Relative quantitation of gene expression. User bulletin No. 2. ABI prism 7700 Sequence Detection System. PE Applied Biosystems 1997
28. Hu N, Qian L, Hu Y, Shou J, Wang C, Giffen C, Wang Q, Wang Y, Goldstein AM, Emmert-Buck M and Taylor PR. Quantitative real-time RT-PCR validation of differential mRNA expression of SPARC, FADD, Fascin, COL7A1, CK4, TGM3, ECM1, PPL and EVPL in esophageal squamous cell carcinoma. BMC Cancer 2006; 6: 1-9.
29. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE and Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 2000; 21: 147-151.
30. Catteau A, Harris WH, Xu CF and Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18: 1957-1965.
31. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J and Brown R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001; 158: 1121-1127.
32. Wiley A, Katsaros D, Chen H, de la Rigault Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D and Yu H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006; 107: 299-308.
33. Dhillon VS, Aslam M and Husain SA. The contribution of genetic and epigenetic changes in granulosa cell tumors of ovarian origin. Clin Cancer Res 2004; 10: 5537-5545.
34. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA and Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95: 6870-6875.
35. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, Palazzo JP, Fishel R and Goodfellow PJ. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999; 8: 661-666.
36. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS and Ho JC. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999; 59: 159-164.
37. Strathdee G, MacKean MJ, Illand M and Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335-2341.
38. Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA and Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 2003; 98: 2199-2206.
39. Gifford G, Paul J, Vasey PA, Kaye SB and Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10: 4420-4426.
40. Zhang H, Zhang S, Cui J, Zhang A, Shen L and Yu H. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 2008; 48: 505-509.
41. Dhillon VS, Shahid M and Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 2004; 3: 33.
42. Rimel BJ, Huettner P, Powell MA, Mutch DG and Goodfellow PJ. Absence of MGMT promoter methylation in endometrial cancer. Gynecol Oncol 2009; 112: 224-228.